Atreca (Atreca) EBIT per Share : $-1.97 (TTM As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Atreca EBIT per Share?

Atreca's EBIT per Share for the three months ended in Sep. 2023 was $-0.40. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.97.

During the past 3 years, the average EBIT per Share Growth Rate was 17.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 31.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Atreca's EBIT per Share or its related term are showing as below:

BCEL' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 17.8 Med: 37.6 Max: 40.6
Current: 17.8

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Atreca was 40.60% per year. The lowest was 17.80% per year. And the median was 37.60% per year.

BCEL's 3-Year EBIT Growth Rate is ranked better than
68.81% of 1305 companies
in the Biotechnology industry
Industry Median: 3.5 vs BCEL: 17.80

Atreca's EBIT for the three months ended in Sep. 2023 was $-15.79 Mil.

Atreca EBIT per Share Historical Data

The historical data trend for Atreca's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atreca EBIT per Share Chart

Atreca Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-11.75

-4.26

-2.70

-2.95

-2.52

Atreca Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT per Share	Get a 7-Day Free Trial															-0.60	-0.52	-0.55	-0.50	-0.40

Atreca EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Atreca's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-97.157	/	38.594
=	-2.52

Atreca's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-15.793	/	39.355
=	-0.40

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.97

Atreca (OTCPK:BCEL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Atreca EBIT per Share Related Terms

Thank you for viewing the detailed overview of Atreca's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Atreca (Atreca) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atreca Inc (OTCPK:BCEL) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

0C1:Germany

Address

835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.atreca.com

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Executives

Felix Baker	other: Former 10% Owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	other: Former 10% Owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	other: Former 10% Owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	other: Former 10% Owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Roger Richard Ruiz	officer: VP of Finance	C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Stephen E Gould	officer: Chief Scientific Officer	C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Tito Serafini	director, officer: Chief Strategy Officer	C/O ATRECA, INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Phillips Courtney	officer: General Counsel & Secretary	ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Philippe C Bishop	officer: Chief Medical Officer	C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
John A Orwin	director, officer: President & CEO	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Stacey Ma	director	C/O ATRECA, INC., 835 INDUSTRIAL RD., SUITE 400, SAN CARLOS CA 94070
Stephen R Brady	director	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Norman Michael Greenberg	officer: Chief Scientific Officer	500 SAGINAW DRIVE, REDWOOD CITY CA 94063
William Hewitt Robinson	director	500 SAGINAW DRIVE, REDWOOD CITY CA 94063